Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

Analyst Ratings

Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (?)
Ratings Breakdown: 10 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $23.18 (468.18% upside)

Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016WedbushReiterated RatingNeutral$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016GabelliReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageMarket Perform$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2015SunTrust Banks Inc.UpgradeNeutral -> Buy$12.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015GuggenheimLower Price TargetBuy$60.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Robert W. BairdDowngradeOutperform -> Neutral$41.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Cantor FitzgeraldDowngradeBuy -> Hold$50.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Nomura Holdings Inc.DowngradeBuy -> Neutral$54.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Stifel NicolausDowngradeBuy -> Hold$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015($0.54)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.46)($0.41)($0.44)
Q2 20162($0.48)($0.44)($0.46)
Q3 20162($0.54)($0.47)($0.51)
Q4 20162($0.59)($0.47)($0.53)
Q1 20171($0.56)($0.56)($0.56)
Q2 20171($0.58)($0.58)($0.58)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateHeadline
07/23/16 10:44 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/23/16 10:44 AMTetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) Sellers Covered 19.37% of Their Shorts - Consumer Eagle
07/20/16 08:00 PMTetraphase Pharmaceuticals Inc. (TTPH) Drops 5.73% on July 19 - Equities.com
07/13/16 09:49 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 09:49 AMHow Analysts Rated Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Last Week? - Consumer Eagle
07/11/16 07:55 AMStock Rating Watch and Earnings Insight for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Press Telegraph
07/08/16 09:47 AMTetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) Short Interest Decreased By 11.01% - Engelwood Daily
07/08/16 09:47 AMCan Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Improve on the Earnings Front? - Engelwood Daily
07/08/16 09:47 AMCompany Stock Focus for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH): Which Way Will Shares Head? - Press Telegraph
07/07/16 07:02 PMHeightened Volatility Check on: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Engelwood Daily
07/04/16 05:54 PMShare Performance Recap for: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Press Telegraph
07/01/16 09:35 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Earnings Glance and Target Price Review - Engelwood Daily
06/30/16 07:05 PMAre Analysts Bullish Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) After Last Week? - Engelwood Daily
06/30/16 07:05 PMStock under Analysts' radar: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - News Oracle
06/29/16 06:51 PMTetraphase Pharmaceuticals : Added to the Russell Microcap Index
06/28/16 06:50 PMTetraphase Pharmaceuticals Added to the Russell Microcap® Index - GlobeNewswire (press release)
06/28/16 06:50 PMCheck on Share Volatility: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Engelwood Daily
06/28/16 06:50 PMTetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) Sellers Covered 11.01% of Their Shorts - Engelwood Daily
06/28/16 08:51 AMTetraphase Pharmaceuticals Added to the Russell Microcap® Index - [at noodls] - WATERTOWN, Mass., June 28, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant ...
06/28/16 07:41 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Updated Price Targets - FTSE News
06/27/16 07:25 AMShare Update and Earnings Review for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Press Telegraph
06/27/16 07:25 AMNext Weeks Broker Price Targets For Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Fiscal Standard
06/26/16 07:34 AMCovering the Bases on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH): Where is the Stock Going? - Press Telegraph
06/23/16 07:42 PMHynes Keller & Hernandez, LLC Announces Investigation of Tetraphase Pharmaceuticals Inc. (TTPH) - PR Newswire (press release)
06/23/16 12:16 PMHynes Keller & Hernandez, LLC Announces Investigation of Tetraphase Pharmaceuticals Inc. (TTPH) - [PR Newswire] - NEW YORK, June 23, 2016 /PRNewswire/ -- Hynes Keller & Hernandez, LLC is investigating potential claims against the Board of Directors of Tetraphase Pharmaceuticals Inc. ("Tetraphase" or the ...
06/23/16 09:29 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock Momentum Hits EXTREME Weakness - CML News
06/21/16 06:26 PMTetraphase Pharmaceuticals : Presents Antibiotics Pipeline Data at ASM Microbe 2016
06/21/16 07:37 AMTetraphase Pharma (TTPH) Presents Data from IGNITE1 and IGNITE2 at ASM Conference
06/20/16 06:29 PMTetraphase Pharma (TTPH) Presents Data from IGNITE1 and IGNITE2 at ASM Conference - StreetInsider.com
06/20/16 03:29 PMTetraphase Pharmaceuticals Presents Antibiotics Pipeline Data at ASM Microbe 2016 - [at noodls] - WATERTOWN, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant ...
06/16/16 07:06 PMTetraphase Pharmaceuticals Inc. (TTPH) Jumps 5.01% on June 16 - Equities.com
06/15/16 07:19 AMTetraphase Pharmaceuticals to Present at 2016 JMP Securities Life Sciences Conference - [at noodls] - WATERTOWN, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant ...
06/14/16 03:13 PMTETRAPHASE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/08/16 10:04 AMTETRAPHASE PHARMACEUTICALS INC. (NASDAQ:TTPH) Financial Condition Compared to S&P 500 - CML News
06/06/16 07:06 PMTop Earnings to Watch for: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - iStreetWire
06/03/16 09:59 AMShare Rating Focus on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - HNN
06/02/16 07:29 PMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Quarterly EPS Estimate At $-0.51 - Investor Newswire - Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Quarterly EPS Estimate At $-0.51Investor NewswireFirst Call stated that Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) can touch $9.50 in coming one year. For the next quarter, the per-share earnings target is $-0.51 and for ongoing fiscal at $-1.96. EPS target for next year is $-2.04 versus the mean ...
06/02/16 10:12 AMTarget Price and Stock Performance Rundown for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - HNN - Target Price and Stock Performance Rundown for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)HNNDuring the latest trading session, Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) shares traded +0.22%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
06/02/16 10:12 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock Update & Estimates - Stock Tick Tock - Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to post earnings of $-0.45 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely ...and more »
05/30/16 10:26 PMNext Weeks Broker Price Targets For Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Share Trading News - Next Weeks Broker Price Targets For Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)Share Trading News05/13/2016 – Tetraphase Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Wedbush. They now have a USD 4 price target on the stock. 04/11/2016 – BMO Capital Markets began new coverage on Tetraphase Pharmaceuticals, Inc. giving ...and more »
05/29/16 10:47 AMCDC: 1st US case of germ resistant to last resort drug - Industry experts said small, lesser-known companies with promising approaches to tackling resistant superbugs included: Entasis Therapeutics, an AstraZeneca PLC spinoff, Tetraphase Pharmaceuticals Inc (TTPH.O); and Achaogen Inc (AKAO.O). "There is no ...
05/29/16 10:47 AMWhat You Need to Know About New Antibiotic-Resistant Superbug Bacteria - Industry experts said small, lesser-known companies with promising approaches to tackling resistant superbugs included: Entasis Therapeutics, an AstraZeneca PLC spinoff, Tetraphase Pharmaceuticals Inc (TTPH.O); and Achaogen Inc (AKAO.O). He said he planned ...
05/29/16 06:00 AMNew incentives needed to develop antibiotics to fight superbugs - [Reuters - UK Focus] - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment, companies and industry experts said. Drugmakers on Friday acknowledged that in the absence of a new way of compensating them, it simply does not make economic sense to pour serious resources into work on new antibiotics. "The return on investment based on the current commercial model is not really commensurate with the amount of effort you have to put into it," said David Payne, who heads GlaxoSmithKline PLC (Other OTC: GLAXF - news) 's antibiotics drug group.
05/26/16 07:18 AMTarget Check and Stock Performance Recap Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Wall Street Hints and News - Target Check and Stock Performance Recap Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)Wall Street Hints and NewsIn recent session activity, Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) shares have traded +1.64%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has ...and more »
05/24/16 12:28 PMTetraphase Pharma (TTPH) Will Present at ASM Microbe 2016; Includes Eravacycline Phase 3 Data - Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference ...
05/23/16 07:46 AMTetraphase Pharmaceuticals Announces Presentation of Data at ASM Microbe 2016 - [at noodls] - WATERTOWN, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 ...
05/20/16 12:13 PMAnalyst Rating Check on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Wall Street Hints and News - Analyst Rating Check on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 2.71 on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Analysts that cover ...and more »
05/20/16 12:13 PMRevenue Update on Tetraphase Pharmaceuticals Inc(NASDAQ:TTPH) - Trade Calls - Revenue Update on Tetraphase Pharmaceuticals Inc(NASDAQ:TTPH)Trade CallsTetraphase Pharmaceuticals Inc(NASDAQ:TTPH) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 4, 2016. Company reported revenue of $1.96M. Analysts estimated a revenue of $2.20M. Earnings ...
05/20/16 08:30 AMThe Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase -
05/19/16 11:50 AMMoved down in the past Week: Tetraphase Pharmaceuticals, Inc.'s (TTPH) - Is stories - Is storiesMoved down in the past Week: Tetraphase Pharmaceuticals, Inc.'s (TTPH)Is storiesTetraphase Pharmaceuticals, Inc.'s (TTPH) witnessed a loss of -0.80% in recent trading period with closing price of $ 3.71. The company's last traded volume of 0.61 million shares was above it's an average volume of 0.92 million shares. In the trailing ...Market Analyst's Price Target Overview about two Stocks: California Resources Corporation (NYSE:CRC), Linn Energy ...WsNews 4investorsall 218 news articles »

Social

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company's TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TTPH
  • CUSIP:
Key Metrics:
  • Previous Close: $4.08
  • 50 Day Moving Average: $4.16
  • 200 Day Moving Average: $4.69
  • P/E Ratio: N/A
  • P/E Growth: -0.01
  • Market Cap: $149.35M
  • Beta: 2.71
  • Current Year EPS Consensus Estimate: $-1.96 EPS
  • Next Year EPS Consensus Estimate: $-2.04 EPS
Additional Links:
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Chart for Saturday, July, 23, 2016